2.80% -3.58

Novartis Ag Adr (NVS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione Frazionamento azionario Storia dei dividendi

Novartis Ag Adr Borsa (NVS) Ultime notizie

Sep 12, 2025

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Sep 12, 2025

Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha

Sep 12, 2025

Sep 10, 2025

Global Industrial Biomanufacturing Market Report 2026-2036: Sustainability, Synthetic Biology, and Circular Economy Drive Growth - GlobeNewswire Inc.

Sep 10, 2025

Sep 09, 2025

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com

Sep 09, 2025

Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news

Sep 09, 2025

Sep 03, 2025

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Sep 03, 2025

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva

Sep 03, 2025

Aug 19, 2025

Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn

Aug 19, 2025

Aug 18, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Aug 18, 2025

Aug 17, 2025

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com

Aug 17, 2025

Aug 11, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis

Aug 11, 2025

Aug 10, 2025

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva

Aug 10, 2025

Aug 07, 2025

What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar

Aug 07, 2025

Jul 31, 2025

Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail

Jul 31, 2025

Jul 29, 2025

INCY's Q2 Earnings & Revenues Beat Estimates On Higher Product Sales - Barchart.com

Jul 29, 2025

Jul 25, 2025

NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jul 25, 2025

Jul 18, 2025

Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar

Jul 18, 2025

Jul 17, 2025

Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com

Jul 17, 2025

Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria

Jul 17, 2025

Jul 15, 2025

Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com

Jul 15, 2025

Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - Yahoo Finance

Jul 15, 2025

Jul 10, 2025

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com

Jul 10, 2025

Jul 03, 2025

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView

Jul 03, 2025

Jul 01, 2025

MRK

$82.81

2.75%

NVO

$54.87

1.05%

AMGN

$276.39

2.24%

GILD

$114.55

2.81%

ABBV

$218.34

0.85%

Novartis Ag Adr (NVS)

Novartis Ag Adr Borsa (NVS) Ultime notizie

Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus

Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha

Global Industrial Biomanufacturing Market Report 2026-2036: Sustainability, Synthetic Biology, and Circular Economy Drive Growth - GlobeNewswire Inc.

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com

Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news

Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva

Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva

What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar

Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail

INCY's Q2 Earnings & Revenues Beat Estimates On Higher Product Sales - Barchart.com

NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar

Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com

Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria

Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com

Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - Yahoo Finance

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com

Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView

Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com

Novartis completes acquisition of Regulus Therapeutics - Novartis

5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com

Simile a NVS